Sinotau
Sinotau (先通医药) is a Chinese pharmaceutical innovator specializing in the research, development, production, clinical application, and academic promotion of radiopharmaceuticals (nuclear medicine). Formally established in 2014, the company focuses on three therapeutic areas — oncology, neurology, and cardiology — and has brought its first innovative product, 欧韦宁 (Florbetaben Fluorine-18 injection for PET brain imaging), to market alongside a pipeline of 10+ products in development. Sinotau operates multiple R&D and production facilities, employs 400+ staff, and holds 80+ authorized patents. It was surfaced as a portfolio company of Qiming Venture Partners. As a corporate radiopharmaceutical manufacturer, Sinotau publishes a corporate marketing website but no public developer platform, API, or technical documentation surface at this time.
Sinotau is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Radiopharmaceuticals, Nuclear Medicine, and Healthcare.
Kin Score
Markets this provider is in provisional
The Kin Score Market layer reads a provider inside its market: its position, and how deep its integrations go. Depth is only comparable within a position. Provisional and unweighted: not part of the Kin Score or agent readiness.
| Market | Position | Depth | Registered MCP server | Declares compatibility |
|---|---|---|---|---|
| FDA Device Establishments (radiology, nuclear medicine, cardiovascular, robotic surgery) | undeclared | - | - | - |
Registered MCP server and declares compatibility are report only — not weighted. Undeclared means we found nothing we can read, so there is no number: we never infer integrations.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 3
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.